THE USE OF VITAMINS AND MINERALS IN SKELETAL HEALTH: AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT

Daniel L. Hurley, MD, FACE[1]; Neil Binkley, MD, FACE[2]; Pauline M. Camacho, MD, FACE[3];
Dima L. Diab, MD, FACE, FACP, CCD[4]; Kurt A. Kennel, MD, FACE[5];
Alan Malabanan, MD, FACE, CCD[6]; Vin Tangpricha, MD, PhD, FACE[7]

Abbreviations:
25(OH)D = 25-hydroxyvitamin D; **BMD** = bone mineral density; **CV** = cardiovascular; **GI** = gastrointestinal; **IOM** = Institute of Medicine; **PTH** = parathyroid hormone; **RCT** = randomized controlled trial; **αTF** = α-tocopherol; **ucOC** = undercarboxylated osteocalcin; **VKA** = vitamin K antagonist; **WHI** = Women's Health Initiative

INTRODUCTION

The desire to maintain health, including bone health, into old age has led to almost one-half of the population and 70% of older adults in the United States (1) and up to 26% in Europe (2,3) using dietary supplements. Dietary supplements allow for randomized controlled trials (RCTs) that can assess a single nutrient. However, in nutrient studies, it is difficult to account for the impact of food and food fortification on skeletal outcomes. The ability to accurately quantify the effect of an individual nutrient on bone health is confounded by methodological issues and the time lag to assess outcomes. Multiple challenges exist to define what constitutes optimal nutrition for bone health. As stated by Dr. Robert Heaney, "…the Institute of Medicine (IOM) makes recommendations concerning intakes of something like nineteen essential nutrients … for virtually all of them, there are still major unresolved questions … most fundamental, what is normal?" (4). Challenges in defining nutritional adequacy are related in part to study design. Baseline nutrient assessment can also be challenging due to variability in daily food consumption. Furthermore, the interactions between nutrients in food, rather than provision of a single nutrient as a supplement, may have important effects. Finally, it seems implausible that a single nutrient amount is optimal for all individuals, regardless of gender, age, ethnicity, body size, and comorbidities. Thus, it is unrealistic to expect systematic reviews or meta-analyses to provide a simple "one size fits all" definition of optimal nutritional status for skeletal health. Nonetheless, clinicians are commonly asked for advice regarding proper nutrient intake to maintain health. Recognizing that additional data are sorely needed, the aim of this position statement is to outline our current understanding of optimal nutrition to maximize bone gain, minimize bone loss, and reduce fragility fracture risk until future studies provide more clarity.

SKELETAL HEALTH THROUGHOUT LIFE

Osteoporosis is an age-related skeletal disorder of compromised bone strength, predisposing to an increased risk of fracture (5). Modifiable determinants of adult bone health, to include nutrition, influence accrual of peak bone

mass and size, and nutrition may have its greatest influence on adult bone health by affecting early skeletal growth (6). Bone growth generally tracks at a consistent trajectory during youth until puberty, when bone turnover and nutrient demand markedly increase. Depending on the skeletal site, peak bone mass occurs by the end of the second or early in the third decade of life. Supported by sufficient nutrition, bone mass and bone turnover remain relatively stable in midlife. Despite metabolic demands during pregnancy and lactation for fetal bone growth, transient changes in maternal regional or systemic skeletal turnover are without enduring consequence on skeletal integrity (7).

Menopause-related estrogen deficiency leads to an increase in bone remodeling. The rate of bone resorption exceeds formation, leading to micro-architectural deterioration and loss of both cortical and trabecular bone. Optimal nutrition can attenuate but not prevent age-related decline in bone strength seen in both women and men, although nutritional status can impact fracture risk with aging through nonskeletal risk factors (i.e., physical function associated with sarcopenia).

Nutrition supplies the required substrate for the cellular activity, tissue structure, and function of all components of bone. The noncellular bone tissue consists of minerals (i.e., calcium, phosphate, and magnesium), collagen, and noncollagenous proteins. Minerals strengthen the collagen-protein matrix while also serving as a source of important ions for bodily homeostasis. Thus, growth and maintenance of skeletal tissue requires provision of adequate nutrients during each stage of life (8) (Table 1).

CALCIUM

Calcium and phosphorus represent the two principal minerals that form hydroxyl apatite, the major component of bone. The dairy food group is most associated with bone health, with recommended intake of two to three servings a day. Dairy products contain calcium, phosphorus, magnesium, potassium, and protein, and milk consumption has been positively associated with bone health. Adolescent girls who ingest greater amounts of calcium have a higher bone mineral density (BMD), and children and adults consuming low-calcium diets are at risk of osteoporosis and fractures (9-11). Few clinical trials have assessed the effects of calcium supplementation on BMD and fracture risk independent of vitamin D administration. Two RCTs of calcium supplementation in elderly women reported reduced bone turnover and decreased bone loss (12,13). A Cochrane meta-analysis reported calcium alone was not superior to vitamin D alone in preventing fractures in postmenopausal women and older men (14). However, several meta-analyses showed that calcium given with vitamin D reduces vertebral and nonvertebral fracture risk (15,16), consistent with vitamin D's action to improve gastrointestinal (GI) absorption of calcium and ensure adequate bone mineralization.

Calcium supplementation has been reported to increase the risk of cardiovascular (CV) disease in cohort studies, clinical trials, and meta-analyses of previously completed trials (17-19). However, these findings have not been validated in recent studies. A large prospective study of over 9,000 participants taking up to 1,000 mg of calcium daily and followed for 10 years demonstrated no increased risk of CV mortality (20). An updated meta-analysis of RCTs, prospective cohort studies, and case-control studies reported no CV outcome risk in individuals consuming dietary or supplemental calcium up to 2,000 to 2,500 mg/day (21). The National Osteoporosis Foundation and the American Society for Preventative Cardiology stated that calcium intake not exceeding 2,000 to 2,500 mg/day should be considered safe from CV risk. The American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis recommend sufficiency of both calcium and vitamin D as part of the treatment regimen (22). A patient's total calcium intake should be assessed from both the diet and any supplement use, and the total daily amount of calcium should not exceed 1,200 to 1,500 mg. Studies suggest that it is most prudent to obtain calcium from food sources and to use supplements only as needed to reach the recommended total calcium intake.

NONCALCIUM MINERALS

Approximately 85% of the body's phosphorus is found in bone. Phosphate is plentiful in most foods, particularly in processed foods and sodas. Phosphate homeostasis occurs primarily by renal phosphate excretion through the effects of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23)/Klotho. Phosphate is readily absorbed in the gut, enhanced to some extent by 1,25-dihydroxyvitamin D. Insufficient phosphate intake can lead to impaired bone mineralization and rickets or osteomalacia, although inadequate intake is rarely a concern, except for persons experiencing starvation. Data suggest increased dietary phosphate intake is associated with increased PTH and FGF-23 levels and increased bone resorption (23). However, excessive phosphate consumption does not interfere with calcium absorption if there is adequate calcium intake (24) and does not seem to be associated with a lower BMD (25). Inaccurate estimates of dietary phosphate intake, the association of inorganic acid load with dietary phosphate, and the presence of a circadian rhythm of serum phosphate are all factors that might affect nutrient studies of phosphate (26). Phosphate supplementation in otherwise healthy adults is not recommended and may be detrimental to bone, particularly in those with compromised renal function or low calcium intake.

Magnesium, an intracellular cation and cofactor for multiple enzyme systems, is necessary for both calcium and potassium homeostasis. Although found widely in

	Essential nutrient for growth and maintenance	**Studies include RCTs**	**Effect on BCM**	**Effect on BMD**	**Effect on vertebral fractures**	**Effect on non-vertebral fractures**	**Recommended daily dose for bone health (adult RDA for 98% population health)**
Minerals							
Calcium[a]	Yes	Yes	+	+	+	+	1,000-1,200 mg/day (1,000-1,200 mg)
Phosphorus[b]	Yes						? (700 mg)
Magnesium	Yes			0 / +			? (320-420 mg)
Fluoride[c]	Yes	Yes	+	0 / +	0 / +	− / 0	? (3-4 mg)
Strontium[d]	No	Yes	+	+	+	+	? (RDA not available)
Boron	No						? (RDA not available; UL 20 mg/d)
Vitamins							
A[e]	Yes						? (2,333-3,000 IU)
C[f]	Yes	Yes		0 / +	0 / +	0 / +	? (75-90 mg)
D[g]	Yes	Yes	+	+	+	+	1,000-2,000 IU/d (600 IU)
E[h]	Yes			0 / +			? (15 mg = 22.5 IU)
K[i]	Yes		0 / +	+	+		? (RDA not available; AI 90-120 µg/d)
Trace Elements							
Copper	Yes			0 / +			? (900 µg)
Iron[j]	Yes			+			? (8-18 mg)
Manganese	Yes			0			? (RDA not available; AI 1.8-2.3 mg/d)
Selenium	Yes		+	0 / +			? (55 µg)
Zinc	Yes			0 / +			? (8-11 mg)

Abbreviations: AI = adequate intake; BCM = biochemical marker; BMD = bone mineral density; RCT = randomized controlled trial; RDA = recommended daily allowance; UL = tolerable upper intake level.
(0) no effect, (−) negative effect, (+) positive effect, (?) dose unknown. Blank fields indicate no or limited data.
[a]Prevents bone loss. Vertebral and nonvertebral fractures reduced when given with vitamin D (few trials with calcium alone).
[b]Increased intake associated with elevated parathyroid hormone and bone resorption, but does not lower BMD if calcium intake adequate.
[c]Small RCTs show reduced vertebral fractures only. Meta-analysis showed no benefit for reducing vertebral fractures and an increased nonvertebral fracture risk.
[d]At increased doses, especially with low calcium intake, strontium has been shown to induce rickets and osteomalacia in animals, and persons with renal failure may be at increased risk. Reported association with increased cardiovascular risk.
[e]Variable effects seen on both BMD (positive or no effect) and fracture risk (both decreased and increased risk).
[f]Non-RCT studies generally show a positive relationship with bone health; dose relationship may be U-shaped.
[g]Meta-analyses show that in patients with osteoporosis, antifracture efficacy occurs at 25-hydroxyvitamin D levels ≥30 ng/mL.
[h]Cross-sectional studies generally positive toward bone health by BMD and fracture data; dose relationship may be U-shaped.
[i]Meta-analysis of cross-sectional and longitudinal studies in patients receiving vitamin K agonists suggests no effect on BMD.
[j]Iron RDA requirements higher for premenopausal women (18 mg) versus postmenopausal women and men (8 mg).

foods, 48% of the U.S. population consume less than the recommended daily amount (RDA) of magnesium (27). Magnesium homeostasis is primarily regulated by the kidneys, and deficiency may occur from renal causes (diuretics, diuresis, tubular necrosis, etc.) or GI malabsorption. Hypomagnesemia may impair osteoblast function, decrease PTH and 1,25-dihydroxyvitamin D production or action, and increase osteoclast activation (27). Effects of magnesium supplementation on BMD are variable. A Women's Health Initiative (WHI) study analysis by food questionnaire found hip and whole-body BMD significantly related to magnesium intake, although fracture risk

was unchanged except in women at the highest quintiles of magnesium intake (28). At present, there is no evidence to support routine magnesium supplementation in otherwise healthy adults.

Fluoride is naturally present in soil and water and consequently found in the food chain. Fluoride is absorbed completely in the GI tract. Fluoride absorption drops to 50 to 80% when complexes form with proteins, calcium, and other minerals. Approximately 95% of bodily fluoride is found in the bones and teeth, and fluoroapatite is antimicrobial and strengthens dental enamel. Fluoride stimulates bone formation at low doses, and although the mechanism is unclear, possible means include increasing osteoblast number and function (29). At a dose of 75 mg/day, bone may become abnormally mineralized and susceptible to fracture (30), and skeletal fluorosis has developed from excessive consumption of fluoride in tea (31). Conversely, although 25 mg twice daily dosing of slow-release fluoride showed some success to increase BMD and reduce vertebral fractures (32,33), a meta-analysis reported no benefit for reducing vertebral fractures and an increased nonvertebral fracture risk after 4 years of treatment (34). Thus, although controversial, fluoride supplementation is not recommended for skeletal health.

Strontium is also a naturally occurring mineral in soil and water. Strontium has chemical similarity to calcium but is found primarily on the surface of bone apatite crystals, and only a small amount replaces calcium within the crystal lattice. Strontium results in a reduced calcium and increased carbonate content of the apatite crystal, thereby enlarging the crystal lattice size. Strontium is rapidly incorporated into bone and reduces bone resorption while modestly stimulating bone formation. Strontium increases BMD related to effects on bone turnover, but due to physicochemical consequences of replacing calcium within the lattice structure (35) may not improve bone strength. There is no evidence of bone toxicity or impaired mineralization at low doses, but strontium has induced osteomalacia in animals, and there may be increased susceptibility in persons with renal failure (36). Strontium is approved outside the U.S. for the treatment of osteoporosis and reported to decrease the incidence of vertebral and nonvertebral fractures (37,38). However, due to lack of data on bone health and concerns of severe cutaneous drug reactions and increased CV events, strontium supplementation is not recommended for skeletal health. Strontium ranelate is now restricted to severe osteoporosis treatment in Europe due to concerns about its cardiovascular adverse events. In addition, a drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) must be considered in anyone taking strontium ranelate who develops a rash and systemic symptoms, and the drug should be stopped and not recommended for future use.

Boron is a trace element found naturally in plants, and a diet consuming fruits, leafy vegetables, nuts, and legumes is high in boron. Boron does not seem to have a clear biochemical function in humans (39), but it may have a role in reproductive and bone health in animals (40). Boron may stabilize and extend the half-life of vitamin D and estrogen and increase the renal retention of calcium and magnesium, but there are insufficient data to recommend supplementation for skeletal health (41).

Sodium intake increases urinary calcium excretion, thereby potentially increasing the risk for kidney stones and bone loss (42,43). An association of sodium intake with decreased hip (44) or spine BMD (45) is reported, but an analysis of WHI data did not find any association between sodium intake and BMD or hip fracture risk independent of calcium intake (46).

VITAMIN D

Vitamin D is present only in small amounts in food, and it is primarily produced in the skin upon exposure to ultraviolet B radiation (47). Hypovitaminosis D is common when dietary intake is low or poorly absorbed and sun exposure is limited. Vitamin D plays a major role in active GI transport of calcium and may improve muscle function and balance, thereby reducing fall risk (48), which is important for patients with osteoporosis, as falls cause ≥90% of hip fractures. Furthermore, vitamin D might also improve the BMD response to bisphosphonates (49,50). As a result of all these skeletal effects, multiple medical organizations recommend optimizing vitamin D status as a core component in the treatment of osteoporosis. Defining "vitamin D inadequacy" is extremely controversial. RCTs evaluating nutrients are often confounded when "low" nutrient status is not established, since nutrients reach a threshold effect in which greater amounts do not provide enhanced physiologic effects (51). As such, providing vitamin D to volunteers who are vitamin D replete should not be expected to demonstrate beneficial effects. Another major confounder is variability of the 25-hydroxyvitamin D (25[OH]D) assay. Despite being the best determinate of bodily vitamin D status (52), substantial variability between 25(OH)D assays and laboratories persists (53). The Office of Dietary Supplements Vitamin D Standardization Program (VDSP) facilitates standardization of the intra-assay variability and bias of 25(OH)D measurements, recommending a 10% coefficient of variation (CV) for clinical laboratories (54). It is important to appreciate this assay variability. For example, a 25(OH)D laboratory result of 30 ng/mL meeting the 10% CV VDSP recommendation means that the "true" value is between 24 and 36 ng/mL (55). Such variability in 25(OH)D results represents a major challenge to meta-analyses of RCTs (56).

Based on this background of uncertainty, systematic reviews find vitamin D supplementation with daily doses of ≥800 IU to reduce hip and nonvertebral fractures (57,58). A reasonable clinical approach is a vitamin D intake of

≥1,000 IU/day for adults ≥50 years of age, as vitamin D inadequacy is common in those with a low BMD or prior fragility fracture. AACE/ACE clinical practice guidelines recommend vitamin D sufficiency be defined as serum 25(OH)D ≥30 ng/mL, based on an increased prevalence of secondary hyperparathyroidism below this level (22). The IOM reviewed virtually the same evidence base and recommended 25(OH)D ≥20 ng/mL to define vitamin D sufficiency (52).

The level that constitutes "high" vitamin D status is similarly controversial. A conservative upper level, based upon 25(OH)D values achieved by highly sun-exposed young adults, is 50 to 60 ng/mL (59). Reasonable approaches to vitamin D assessment and treatment include an initial measurement of 25(OH)D in patients at risk of deficiency, or alternatively, vitamin D supplementation and subsequent 25(OH)D measurement 3 to 4 months later to assess dose adequacy. The amount of vitamin D required to correct deficiency and reach target levels varies among individuals due to as yet poorly understood factors, to include obesity and ethnicity (60). Use of huge single doses of vitamin D is not recommended, as limited data find this approach to paradoxically increase falls and fracture risk (61). It is essential that vitamin D replacement of deficient states be followed by maintenance dosing (e.g., 1,000 to 2,000 IU/day), recognizing that higher doses may be needed in patients with obesity or malabsorption.

OTHER VITAMINS

Vitamin A is known to influence bone content. Vitamin A is derived from retinol ingested as either retinyl esters (animal source foods) or carotenoids (fruits and vegetables) and metabolized to active compounds such as 11-cis-retinal, important for vision, and all-trans-retinoic acid, which is the primary mediator of the biologic actions of vitamin A. The role retinoids play in regulating osteoclastogenesis remains unclear. In a small cross-sectional study, vitamin A levels showed a negative correlation with BMD, but this association disappeared when a multivariate analysis was applied to include other anti-oxidants (62). Plasma retinol levels and carotenoids tested in ambulatory women were found to be associated with lower hip BMD and consistently lower in those with osteoporosis (63). Some studies suggest that moderate intakes of retinol (64) and increased circulating retinol levels (65) may increase fracture risk, whereas others have found no effect on hip BMD (66) or fractures (67,68). In a randomized study of 998 adults, lower fracture risk was suggested with increasing plasma total carotenes after long-term supplementation, but no association was found between plasma retinol levels and fracture risk (69).

Vitamin K is a cofactor of γ-carboxylase and essential for γ-carboxylation of osteocalcin, a major noncollagenous bone matrix protein important in bone mineraliza-tion. Undercarboxylated osteocalcin (ucOC) lacks structural integrity, and its ability to bind to hydroxyapatite is impaired (70). Observational studies suggest diets low in vitamin K are associated with increased fracture risk in older adults (71). However, a recent review of RCTs to assess the impact of fortified foods on bone outcomes assessed both before and after supplementation found only two studies of vitamin K and just one study with folate food fortification, with no effect from folate and inconsistent effects noted with vitamin K (72). One RCT found no effect of vitamin K–fortified milk when compared to calcium, but the study was <4 months in duration and only assessed markers of bone turnover in young premenopausal women (73). The second RCT included postmenopausal women consuming calcium and vitamin D–fortified dairy with or without vitamin K (74). After 1 year, the vitamin K groups had significantly lower serum ucOC ratios and urine deoxypyridinoline bone turnover levels. Significant increases in total body BMD occurred in all treatment groups, with better increases in spine BMD observed only in the vitamin K groups after controlling for 25(OH)D levels and dietary calcium intake.

There are two naturally occurring vitamin K forms; phylloquinone (K1) is the major dietary form (especially in green leafy vegetables), whereas menaquinone-4 (K2) is the main tissue form, to include bone. Vitamin K2 is synthesized by gut bacteria but also present in some foods (fermented soy beans, cheese, and curds). A 2-year RCT with vitamin K1, vitamin D, and calcium or their combination was studied in postmenopausal women without osteoporosis. The group with combined vitamin K, vitamin D, and calcium had significant changes in serum vitamin K1 (+157%), ucOC (–51%), 25(OH)D (+17%), and PTH (–11%), with BMD improvement at the radius but no other skeletal sites (75). A review of eight small RCTs (n = 63 to 241 subjects) of 1 to 2 years in duration showed that menatetrenone, a synthetic vitamin K2, decreased serum ucOC, increased spine BMD, and reduced the incidence of vertebral fractures (70). Although vitamin K antagonists (VKAs) decrease serum bone turnover markers, their link with osteoporosis and fractures remains controversial. A meta-analysis of cross-sectional and longitudinal studies assessed patients treated with VKAs compared to healthy controls or those with a medical illness (76). Compared with healthy controls, only a single study showed significantly lower spine BMD in the VKA group, and findings in the longitudinal studies were not significant. Currently, there is not enough evidence to recommend the use of vitamin K supplements for skeletal health.

There is conflicting evidence of the role of vitamin E on bone health. The most abundant vitamin E isomer present in food and most widely distributed in the body is α-tocopherol (αTF). Supplementation generally shows positive effects in various animal models of osteoporosis, but high-dose αTF may be detrimental to bone. Possible

reasons αTF may be harmful to bone include interference with the effects of vitamin K on bone, blocking other vitamin E isomers beneficial to bone, and its role as a pro-oxidant. Observational studies to assess the skeletal effects of αTF have generally been positive (77). However, several limitations are involved in the interpretation of these studies. The WHI Observational Study and Clinical Trial reported an association between the amount of vitamin E consumed, the αTF level, and BMD (78), and neither serum vitamin E nor other anti-oxidant levels were associated with hip BMD. Due to the heterogeneity of these studies, no recommendation for vitamin E supplementation can be made for bone health.

Vitamin C is found naturally in fruits and vegetables, and it is a common fortification in cereals and juices due to its low toxicity. However, the prevalence of deficiency in the U.S. is reported as 6% (79). Human studies generally showed a positive relationship between vitamin C and bone health, although some suggest that the relationship may be U-shaped, more prominent in certain subgroups and different between dietary and supplemental forms of ascorbic acid (80,81). Many of these observational or cross-sectional studies used varied methods to assess vitamin C intake and differ in effect size and statistical significance. In contrast, the large WHI study found no association between dietary intake, total intake, or serum levels of vitamin C and BMD (78). In addition, the National Health and Nutrition Examination Survey III found inconsistent outcomes between vitamin C status and BMD among 13,080 U.S. adults: positive among premenopausal women, nonlinear for men, and negative in postmenopausal women with no history of smoking or estrogen use (82). Longitudinal study outcomes from the Framingham Osteoporosis Study, using dietary questionnaires to assess vitamin C intake, found mixed results for BMD outcomes over 4 years and no association with fracture risk, although significantly fewer hip and nonvertebral fractures occurred in the highest versus lowest tertile of intake (83). Two small 6- and 12-month RCTs noted positive but different spine and hip BMD effects (84,85). Taken together, the majority of studies have found either positive trends or significant effects of vitamin C on skeletal health. Vitamin C is known to play a role in collagen formation, bone matrix development, osteoblast differentiation, and in limiting bone resorption, but the exact effect that vitamin C may have on bone density is presently unknown (78,80).

MACRONUTRIENTS AND ISOFLAVONES

Protein is a major nutrient essential for collagen synthesis in bone (86). Current IOM guidelines for dietary protein are 0.8 g/kg (87), although maintenance of muscle mass and bone strength was not an endpoint for these RDA requirements. A meta-analysis of cross-sectional studies suggests either no association or a small positive associa-

tion between protein intake and BMD (88). Several studies found inconclusive evidence linking dietary protein intake with fracture risk (89). The prospective Iowa Women's Health Study reported a decreased relative risk of hip fracture across increasing quartiles of animal protein intake, compared to vegetable protein, in postmenopausal women (90). The prospective 5-year Canadian Multicentre Osteoporosis study showed that low protein intakes (<12% of total calories) were associated with almost double the risk of fragility fracture in postmenopausal women and men aged ≥50 years compared to higher (≥15% of total calories) protein consumption (91). The protein source was a determinant of BMD but not fracture risk, whereby greater dairy protein intake was associated with higher BMD compared to plant-based protein. It has been hypothesized that a high-protein (i.e., acid-based) diet is associated with hypercalciuria from bone resorption. However, a recent review concluded that the dietary acid hypothesis is not supported by current evidence (92). In addition, a protein and calcium interaction has been identified, suggesting increased dietary protein is associated with decreased fracture incidence with calcium intakes >800 mg/day, whereas the effect appears reversed during lower calcium intake (93). The balance of evidence suggests that adequate protein intake is an important modifiable risk factor associated with reduced risk of fragility fracture.

Flavonoids are lipid-soluble polyphenols widely distributed in plants and may act as chemical messengers and anti-oxidants. Isoflavones are "natural" or "phyto-estrogens" (e.g., bioactive compounds that bind to the estrogen receptor) found in various plants and foods, most notably soybeans. Tea flavonoids have been suggested to protect against bone loss, but epidemiologic studies have shown mixed results of habitual tea consumption on BMD and fracture risk, and the results from clinical trials are limited (94). There has been increasing interest in whether isoflavones can promote bone health and ameliorate bone loss (95), but studies are conflicting regarding a positive BMD effect (96). There is little support for the use of isoflavone supplements in Western countries due to inconclusive evidence that these compounds improve BMD or decrease fracture risk (97-99).

TRACE ELEMENTS

Trace elements ae essential for the growth, development, and maintenance of body tissues, including bone. Many over-the-counter supplements containing trace elements are advertised as beneficial for bone health and prevention of bone loss, but to date, there are no long-term, high-quality studies that show fracture risk reduction. A recent meta-analysis found lower serum levels of zinc, copper, or iron in patients with osteoporosis than healthy controls (100). In a small cross-sectional study, patients with bone loss were found to have significantly lower

serum levels of zinc and copper, although no differences were observed in those with osteopenia and osteoporosis (101). In postmenopausal women, plasma and red blood cell trace element concentrations were not significantly different between those with and without osteoporosis for zinc, copper, manganese, and selenium (102). A study in postmenopausal women reported a positive association of serum zinc with BMD, but no correlation to serum levels of copper or selenium was observed (103). In contrast, the 6-year, prospective Osteoporosis and Ultrasound Study found that higher selenium levels are associated with lower bone turnover markers and greater BMD in postmenopausal women, both at study baseline and 6-year follow-up (104). Although trace elements are necessary for normal bone development (105), their efficacy in the treatment of osteoporosis remains unclear.

SUMMARY

As defined by the World Health Organization and the Food and Agricultural Organization of the United Nations, fortification refers to "the practice of deliberately increasing the content of an essential micronutrient, that is, vitamins or minerals in a food, irrespective of whether the nutrients were originally in the food before processing or not, so as to provide a health benefit with minimal risk to health" (106). Food fortification has the advantage of delivering essential nutrients to large segments of the population without requiring radical changes in food consumption patterns. Foods used as fortification vehicles vary from country to country, but they generally include cereals and cereal-based products, milk and dairy products, fats and oils, tea and other beverages, and condiments. Certain types of fortification are more accurately called enrichment when micronutrients lost during processing are added back to food.

Debate surrounds the benefits of individual high-dose micronutrient supplementation among well-nourished individuals, and this is true also for skeletal health. Given the study limitations limiting our current knowledge, provision of excess nutrients beyond their threshold of benefit may not produce a greater response. Three critical nutrients for bone health are calcium, vitamin D, and protein, and diets that are inadequate in one may well be inadequate in other nutrients important to skeletal health. Otherwise, optimal nutritional status for bone health is best obtained by consuming a healthful diet and will likely not be met by single nutrient supplementation.

ACKNOWLEDGMENT

DISCLOSURE

REFERENCES

1. **Bailey RL, Gahche JJ, Lentino CV, et al.** Dietary supplement use in the United States, 2003-2006. *J Nutr*. 2011;141:261-266.
2. **Marques-Vidal P, Pécoud A, Hayoz D, et al.** Prevalence and characteristics of vitamin or dietary supplement users in Lausanne, Switzerland: the CoLaus study. *Eur J Clin Nutr*. 2009;63:273-281.
3. **Rovira MA, Grau M, Castañer O, Covas MI, Schröder H.** Dietary supplement use and health-related behaviors in a Mediterranean population. *J Nutr Educ Behav*. 2013;45:386-391.
4. **Heaney RP.** Methods in nutrition science: the bone remodeling transient: interpreting interventions involving bone-related nutrients. *Nutr Rev*. 2001;59:327-334.
5. **Cosman F, de Beur SJ, LeBoff MS, et al.** Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. 2014;25:2359-2381.
6. **Weaver CM, Gordon CM, Janz KF, et al.** The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. *Osteoporos Int*. 2016;27:1281-1386.
7. **Kovacs CS.** Calcium and bone metabolism disorders during pregnancy and lactation. *Endocrinol Metab Clin North Am*. 2011;40:795-826.
8. **Mitchell PJ, Cooper C, Dawson-Hughes B, Gordon CM, Rizzoli R.** Life-course approach to nutrition. *Osteoporos Int*. 2015;26:2723-2742.
9. **Goulding A, Rockell JE, Black RE, Grant AM, Jones IE, Williams SM.** Children who avoid drinking cow's milk are at increased risk for prepubertal bone fractures. *J Am Diet Assoc*. 2004;104:250-253.

10. **Rockell JE, Williams SM, Taylor RW, Grant AM, Jones IE, Goulding A.** Two-year changes in bone and body composition in young children with a history of prolonged milk avoidance. *Osteoporos Int*. 2005;16:1016-1023.

11. **Matkovic V, Goel PK, Badenhop-Stevens NE, et al.** Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. *Am J Clin Nutr*. 2005;81:175-188.

12. **Riggs BL, O'Fallon WM, Muhs J, O'Connor MK, Kumar R, Melton LJ 3rd.** Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. *J Bone Miner Res*. 1998;13:168-174.

13. **Storm D, Eslin R, Porter ES, et al.** Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. *J Clin Endocrinol Metab*. 1998;83: 3817-3825.

14. **Shea B, Wells G, Cranney A, et al.** Calcium supplementation on bone loss in postmenopausal women. *Cochrane Database Syst Rev*. 2003;4:CD004526.

15. **Avenell A, Mak JC, O'Connell D.** Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. *Cochrane Database Syst Rev*. 2014;4:CD000227.

16. **Weaver CM, Alexander DD, Boushey CJ, et al.** Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. *Osteoporos Int*. 2016;27:367-376.

17. **Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR.** Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. *BMJ*. 2011;342:d2040.

18. **Bolland MJ, Avenell A, Baron JA, et al.** Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ*. 2010;341:c3691.

19. **Bolland MJ, Barber PA, Doughty RN, et al.** Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. *BMJ*. 2008;336:262-266.

20. **Langsetmo L, Berger C, Kreiger N, et al.** Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). *J Clin Endocrinol Metab*. 2013;98:3010-3018.

21. **Chung M, Tang AM, Fu Z, Wang DD, Newberry SJ.** Calcium Intake and cardiovascular disease risk: an updated systematic review and meta-analysis. *Ann Intern Med*. 2016;165:856-866.

22. **Camacho PM, Petak SM, Binkley N, et al.** American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2016. *Endocr Pract*. 2016;22(suppl 4): 1-42.

23. **Calvo MS, Uribarri J.** Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population. *Am J Clin Nutr*. 2013;98:6-15.

24. **Bergman C, Gray-Scott D, Chen JJ, et al.** What is next for the Dietary Reference Intakes for bone metabolism related nutrients beyond calcium: phosphorus, magnesium, vitamin D, and fluoride? *Crit Rev Food Sci Nutr*. 2009;49:136-144.

25. **Lee AW, Cho SS.** Association between phosphorus intake and bone health in the NHANES population. *Nutr J*. 2015;14:28.

26. **Calvo MS, Tucker KL.** Is phosphorus intake that exceeds dietary requirements a risk factor in bone health? *Ann N Y Acad Sci*. 2013;1301:29-35.

27. **Rosanoff A, Weaver CM, Rude RK.** Suboptimal magnesium status in the United States: are the health consequences underestimated? *Nutr Rev*. 2012;70:153-164.

28. **Orchard TS, Larson JC, Alghothani N, et al.** Magnesium intake, bone mineral density, and fractures: results from the Women's Health Initiative Observational Study. *Am J Clin Nutr*. 2014;99:926-933.

29. **Everett ET.** Fluoride's effects on the formation of teeth and bones, and the influence of genetics. *J Dent Res*. 2011;90:552-560.

30. **Riggs BL, O'Fallon WM, Lane A, et al.** Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. *J Bone Miner Res*. 1994;9: 265-275.

31. **Izuora K, Twombly JG, Whitford GM, Demertzis J, Pacifici R, Whyte MP.** Skeletal fluorosis from brewed tea. *J Clin Endocrinol Metab*. 2011;96:2318-2324.

32. **Pak CY, Sakhaee K, Adams-Huet B, Piziak J, Peterson RD, Poindexter JR.** Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. *Ann Intern Med*. 1995;123:401-408.

33. **Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS.** Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. *Arch Intern Med*. 2001;161: 2325-2333.

34. **Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G.** Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. *Osteoporos Int*. 2000;11:727-738.

35. **Querido W, Rossi AL, Farina M.** The effects of strontium on bone mineral: a review on current knowledge and microanalytical approaches. *Micron*. 2016;80:122-134.

36. **Marie PJ, Ammann P, Boivin G, Rey C.** Mechanisms of action and therapeutic potential of strontium in bone. *Calcif Tissue Int*. 2001;69:121-129.

37. **Meunier PJ, Roux C, Seeman E, et al.** The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. *N Engl J Med*. 2004;350:459-468.

38. **Reginster JY, Felsenberg D, Boonen S, et al.** Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. *Arthritis Rheum*. 2008;58:1687-1695.

39. **Nielsen FH.** Update on human health effects of boron. *J Trace Elem Med Biol*. 2014;28:383-387.

40. **Price CT, Langford JR, Liporace FA.** Essential nutrients for bone health and a review of their availability in the average North American diet. *Open Orthop J*. 2012;6:143-149.

41. **Institute of Medicine; Panel on Micronutrients.** Subcommittees on upper reference levels of nutrients and of interpretation and use of Dietary Reference Intakes. Chapter 13: arsenic, boron, nickel, silicon, and vanadium. In: *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc*. Washington D.C.: National Academies Press; 2001: DOI: 10.17226/10026.

42. **Nordin BE, Need AG, Morris HA, Horowitz M.** The nature and significance of the relationship between urinary sodium and urinary calcium in women. *J Nutr*. 1993;123:1615-1622.

43. **Asaba Y, Ito M, Fumoto T, et al.** Activation of renin-angiotensin system induces osteoporosis independently of hypertension. *J Bone Miner Res*. 2009;24:241-250.

44. **Devine A, Criddle RA, Dick IM, Kerr DA, Prince RL.** A longitudinal study of the effect of sodium and calcium intakes on regional bone density in postmenopausal women. *Am J Clin Nutr*. 1995;62:740-745.

45. **Kim SW, Jeon JH, Choi YK, et al.** Association of urinary sodium/creatinine ratio with bone mineral density in postmenopausal women: KNHANES 2008-2011. *Endocrine*. 2015;49:791-799.

46. **Carbone L, Johnson KC, Huang Y, et al.** Sodium intake and osteoporosis. Findings from the Women's Health Initiative. *J Clin Endocrinol Metab*. 2016;101:1414-1421.

47. **Holick MF.** Vitamin D deficiency. *N Engl J Med*. 2007;357: 266-281.

48. **Moyer VA.** Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2012;157:197-204.

49. **Carmel AS, Shieh A, Bang H, Bockman RS.** The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ mL. *Osteoporos Int*. 2012;23:2479-2487.

50. **Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B.** Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. *Am J Med*. 2004;116:634-639.

51. **Heaney RP.** Guidelines for optimizing design and analysis of clinical studies of nutrient effects. *Nutr Rev*. 2014;72:48-54.

52. **Ross AC, Taylor CL, Yaktine AL, et al.** Institutes of Medicine; Committee to review dietary reference intakes for vitamin D and calcium. In: *Dietary Reference Intakes for Calcium and Vitamin D*. National Academies Press; 2011. DOI: 10.17226/13050.

53. **Carter GD, Berry JL, Gunter E, et al.** Proficiency testing of 25-hydroxyvitamin D (25-OHD) assays. *J Steroid Biochem Mol Biol*. 2010;121:176-179.

54. **Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM.** Vitamin D status as an international issue: national surveys and the problem of standardization. *Scand J Clin Lab Invest Suppl*. 2012;243:32-40.

55. **Lappe JM, Binkley N.** Vitamin D and sarcopenia/falls. *J Clin Densitom*. 2015;18:478-482.

56. **Binkley N, Dawson-Hughes B, Durazo-Arvizu R, et al.** Vitamin D measurement standardization: the way out of the chaos. *J Steroid Biochem Mol Biol*. 2017;173:117-121.

57. **Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B.** Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA*. 2005;293:2257-2264.

58. **Bischoff-Ferrari HA, Willett WC, Orav EJ, et al.** A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med*. 2012;367:40-49.

59. **Luxwolda MF, Kuipers RS, Kema IP, Dijck-Brouwer DA, Muskiet FA.** Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/L. *Br J Nutr*. 2012;108:1557-1561.

60. **Holick MF, Binkley N, Bischoff-Ferrari HA, et al.** Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96:1911-1930.

61. **Sanders KM, Stuart AL, Williamson EJ, et al.** Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA*. 2010;303:1815-1822.

62. **De França NA, Camargo MB, Lazaretti-Castro M, Martini LA.** Antioxidant intake and bone status in a cross-sectional study of Brazilian women with osteoporosis. *Nutr Health*. 2013;22:133-142.

63. **Maggio D, Polidori MC, Barabani M, et al.** Low levels of carotenoids and retinol in involutional osteoporosis. *Bone*. 2006;38:244-248.

64. **Feskanich D, Singh V, Willett WC, Colditz GA.** Vitamin A intake and hip fractures among postmenopausal women. *JAMA*. 2002;287:47-54.

65. **Michaëlsson K, Lithell H, Vessby B, Melhus H.** Serum retinol levels and the risk of fracture. *N Engl J Med*. 2003;348:287-294.

66. **Ballew C, Galuska D and Gillespie C.** High serum retinyl esters are not associated with reduced bone mineral density in the Third National Health and Nutrition Examination Survey, 1988-1994. *J Bone Miner Res*. 2001;16:2306-2312.

67. **Lim LS, Harnack LJ, Lazovich D, Folsom AR.** Vitamin A intake and the risk of hip fracture in postmenopausal women: the Iowa Women's Health Study. *Osteoporos Int*. 2004;15:552-559.

68. **Barker ME, McCloskey E, Saha S, et al.** Serum retinoids and beta-carotene as predictors of hip and other fractures in elderly women. *J Bone Miner Res*. 2005;20:913-920.

69. **Ambrosini GLH, Alfonso A, Reid D, et al.** Plasma retinol and total carotenes and fracture risk after long-term supplementation with high doses of retinol. *Nutrition*. 2014;30:551-556.

70. **Iwamoto J.** Vitamin K2 therapy for postmenopausal osteoporosis. *Nutrients*. 2014;6:1971-1980.

71. **Hamidi MS and Cheung AM.** Vitamin K and musculoskeletal health in postmenopausal women. *Mol Nutr Food Res*. 2014;58:1647-57.

72. **Whiting SJ, Kohrt WM, Warren MP, Kraenzlin MI, Bonjour JP.** Food fortification for bone health in adulthood: a scoping review. *Eur J Clin Nutr*. 2016;70:1099-1105.

73. **Kruger MC, Booth CL, Coad J, Schollum LM, Kuhn-Sherlock B, Shearer MJ.** Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women. *Nutrition*. 2006;22:1120-1128.

74. **Kanellakis S, Moschonis G, Tenta R, et al.** Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K (2)): the Postmenopausal Health Study II. *Calcif Tissue Int*. 2012;90:251-262.

75. **Bolton-Smith C, McMurdo ME, Paterson CR, et al.** Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. *J Bone Miner Res*. 2007;22:509-519.

76. **Veronese N, Bano G, Bertozzo G, et al.** Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis. *J Thromb Haemost*. 2015;13:1665-1675.

77. **Chin, K. Y. and S. Ima-Nirwana.** The effects of alpha-tocopherol on bone: a double-edged sword? *Nutrients*. 2014;6:1424-1441.

78. **Wolf RL, Cauley JA, Pettinger M, et al.** Lack of a relation between vitamin and mineral antioxidants and bone mineral density: results from the Women's Health Initiative. *Am J Clin Nutr*. 2005;82:581-588.

79. **Schleicher RL, Carroll MD, Ford ES, Lacher DA.** Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). *Am J Clin Nutr*. 2009;90:1252-1263.

80. **Aghajanian P, Hall S, Wongworawat MD, Mohan S.** The roles and mechanisms of actions of vitamin C in bone: new developments. *J Bone Miner Res*. 2015;30:1945-1955.

81. **Finck H, Hart AR, Jennings A, Welch AA.** Is there a role for vitamin C in preventing osteoporosis and fractures? A review of the potential underlying mechanisms and current epidemiological evidence. *Nutr Res Rev*. 2014;27:268-283.

82. **Simon JA, Hudes ES.** Relation of ascorbic acid to bone mineral density and self-reported fractures among US adults. *Am J Epidemiol*. 2001;154:427-433.

83. **Sahni S, Hannan MT, Gagnon D, et al.** Protective effect of total and supplemental vitamin C intake on the risk of hip fracture--a 17-year follow-up from the Framingham Osteoporosis Study. *Osteoporos Int*. 2009;20:1853-1861.

84. **Chuin A, Labonté M, Tessier D, et al.** Effect of antioxidants combined to resistance training on BMD in elderly women: a pilot study. *Osteoporos Int*. 2009;20:1253-1258.

85. **Ruiz-Ramos M, Vargas LA, Fortoul Van der Goes TI, Cervantes-Sandoval A, Mendoza-Nunez VM.** Supplementation of ascorbic acid and alpha-tocopherol is useful to preventing bone loss linked to oxidative stress in elderly. *J Nutr Health Aging*. 2010;14:467-472.

86. **Bonjour JP.** Dietary protein: an essential nutrient for bone health. *J Am Coll Nutr*. 2005;24(6 suppl):526S-536S.

87. Institute of Medicine, Panel on Macronutrients and Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Washington DC: National Academies Press; 2005: 769-879.

88. **Darling AL, Millward DJ, Torgerson DJ, Hewitt CE, Lanham-New SA.** Dietary protein and bone health: a systematic review and meta-analysis. *Am J Clin Nutr*. 2009;90:1674-1692.

89. **Feskanich D, Willett WC, Stampfer MJ, Colditz GA.** Protein consumption and bone fractures in women. *Am J Epidemiol*. 1996;143:472-479.

90. **Munger RG, Cerhan JR, Chiu BC.** Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. *Am J Clin Nutr*. 1999;69:147-152.

91. **Langsetmo L, Barr SI, Berger C, et al.** Associations of protein intake and protein source with bone mineral density and fracture risk: a population-based cohort study. *J Nutr Health Aging*. 2015;19:861-868.

92. **Fenton TR, Tough SC, Lyon AW, Eliasziw M, Hanley DA.** Causal assessment of dietary acid load and bone disease: a systematic review and meta-analysis applying Hill's epidemiologic criteria for causality. *Nutr J*. 2011;10:41.

93. **Sahni S, Cupples LA, McLean RR, et al.** Protective effect of high protein and calcium intake on the risk of hip fracture in the Framingham offspring cohort. *J Bone Miner Res*. 2010;25:2770-2776.

94. **Shen CL and Chyu MC.** Tea flavonoids for bone health: from animals to humans. *J Investig Med*. 2016;64:1151-1157.

95. North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). *Menopause*. 2011;18:732-753.

96. **Zheng X, Lee SK, Chun OK.** Soy isoflavones and osteoporotic bone loss: a review with an emphasis on modulation of bone remodeling. *J Med Food*. 2016;19:1-14.

97. **Lagari VS, Levis S.** Phytoestrogens in the prevention of post-menopausal bone loss. *J Clin Densitom*. 2013;16:445-449.

98. **Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA.** The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr*. 2004;79:326-333.

99. **Alekel DL, Van Loan MD, Koehler KJ, et al.** The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women. *Am J Clin Nutr*. 2010;91:218-230.

100. **Zheng J, Mao X, Ling J, He Q, Quan J.** Low serum levels of zinc, copper, and iron as risk factors for osteoporosis: a meta-analysis. *Biol Trace Elem Res*. 2014;160:15-23.

101. **Mahdavi-Roshan M, Ebrahimi M, Ebrahimi A.** Copper, magnesium, zinc and calcium status in osteopenic and osteoporotic post-menopausal women. *Clin Cases Miner Bone Metab*. 2015;12:18-21.

102. **Odabasi E, Turan M, Aydin A, Akay C, Kutlu M.** Magnesium, zinc, copper, manganese, and selenium levels in postmenopausal women with osteoporosis. Can magnesium play a key role in osteoporosis? *Ann Acad Med Singapore*. 2008;37:564-567.

103. **Arikan DC, Coskun A, Ozer A, Kilinc M, Atalay F, Arikan T.** Plasma selenium, zinc, copper and lipid levels in postmenopausal Turkish women and their relation with osteoporosis. *Biol Trace Elem Res*. 2011;144:407-417.

104. **Hoeg A, Gogakos A, Murphy E, et al.** Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. *J Clin Endocrinol Metab*. 2012;97:4061-4070.

105. **Zofkova I, Davis M, Blahos J.** Trace elements have beneficial, as well as detrimental effects on bone homeostasis. *Physiol Res*. 2017;66:391-402.

106. **World Health Organization.** Guidelines on food fortification with micronutrients. Available at: http://www.who.int./nutrition/publications.